One day, when my son Dean was just seven weeks old, his grandma was over for a visit. She held him as we chatted, but I had a hard time following the conversation. I was noticing that Dean’s head was bobbing unnaturally, and I heard an unusual grunting sound as he labored to breathe.

A new treatment approach may allow patients to manage AFib more effectively.

Heart disease and Type 2 diabetes aren’t just common. They commonly occur together. So why does the health care system force patients with both conditions to treat one disease at a time?

Preventing a serious cardiac event is a top priority for my patients, but the Institute for Clinical and Economic Review is about to make prevention a whole lot harder.

By Dharmesh Patel, MD

When you or someone you love has a cardiovascular event, life gets real – fast. I’ve seen it with my own patients. The trivial day-to-day concerns evaporate as survival takes sole focus. Health is no longer an afterthought, but a priority.

The coronavirus is killing Americans, but not only in the ways that people expect.

By Keith C. Ferdinand, MD

The toll of COVID-19 has hit the Black community with the power of a hurricane. I should know, because I was in New Orleans 15 years ago for Hurricane Katrina.

By Christie Ballantyne, MD

New medications are expanding the toolbox for health care providers like me to treat patients with high cholesterol. That gives more than 100 million at-risk Americans a better shot at effective, patient-centered care.

Two members of Congress are speaking out on behalf of Medicare patients with cardiovascular risk.

A recent Wall Street Journal article, titled “Heart disease roars back,” reported that one of America’s “greatest achievements” in the past 50 years had been “a huge decline” in death rates from heart disease and stroke.

Earlier, more aggressive cholesterol management could reap important cardiovascular benefits, a recent study reports.

What happens when lower drug prices don’t make medicine more accessible for patients?  Heart patients covered by Medicare Part D are about to find out.

Two isn’t always better than one.  Just ask patients caught in the confusion of two national drug codes for the same cholesterol-lowering medicine.  

A recent Trump administration decision nudges health plans to do right by patients who struggle with high LDL, or “bad,” cholesterol.